TWI491591B - 吲哚化合物及其醫藥用途 - Google Patents

吲哚化合物及其醫藥用途 Download PDF

Info

Publication number
TWI491591B
TWI491591B TW099140715A TW99140715A TWI491591B TW I491591 B TWI491591 B TW I491591B TW 099140715 A TW099140715 A TW 099140715A TW 99140715 A TW99140715 A TW 99140715A TW I491591 B TWI491591 B TW I491591B
Authority
TW
Taiwan
Prior art keywords
group
substituted
alkoxy
alkyl
substituents selected
Prior art date
Application number
TW099140715A
Other languages
English (en)
Chinese (zh)
Other versions
TW201124378A (en
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Michihide Maekawa
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of TW201124378A publication Critical patent/TW201124378A/zh
Application granted granted Critical
Publication of TWI491591B publication Critical patent/TWI491591B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW099140715A 2009-11-25 2010-11-25 吲哚化合物及其醫藥用途 TWI491591B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25

Publications (2)

Publication Number Publication Date
TW201124378A TW201124378A (en) 2011-07-16
TWI491591B true TWI491591B (zh) 2015-07-11

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099140715A TWI491591B (zh) 2009-11-25 2010-11-25 吲哚化合物及其醫藥用途

Country Status (31)

Country Link
US (6) US8299070B2 (enExample)
EP (3) EP3766877A1 (enExample)
JP (6) JP5734628B2 (enExample)
KR (1) KR101766502B1 (enExample)
CN (1) CN102712624B (enExample)
AR (1) AR079164A1 (enExample)
AU (1) AU2010323579C1 (enExample)
BR (1) BR112012012529B1 (enExample)
CA (1) CA2781660C (enExample)
CL (1) CL2012001328A1 (enExample)
CO (1) CO6541645A2 (enExample)
CY (1) CY1117559T1 (enExample)
DK (1) DK2505586T3 (enExample)
ES (1) ES2572935T3 (enExample)
HR (1) HRP20160579T1 (enExample)
HU (1) HUE028016T2 (enExample)
IL (1) IL220009A (enExample)
ME (1) ME02447B (enExample)
MX (1) MX2012006017A (enExample)
MY (1) MY161095A (enExample)
NZ (1) NZ600840A (enExample)
PE (1) PE20121358A1 (enExample)
PH (1) PH12012501021A1 (enExample)
PL (1) PL2505586T3 (enExample)
PT (1) PT2505586E (enExample)
RS (1) RS54910B1 (enExample)
RU (1) RU2556216C2 (enExample)
SI (1) SI2505586T1 (enExample)
SM (1) SMT201600258B (enExample)
TW (1) TWI491591B (enExample)
WO (1) WO2011065402A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PE20151604A1 (es) * 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
TW201625605A (zh) * 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為gpr119調節劑的經取代之稠合雜環類
US20170253577A1 (en) 2014-07-04 2017-09-07 Japan Tobacco Inc. Method for producing indole compound
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
CA3100675A1 (en) * 2018-05-25 2019-11-28 Japan Tobacco Inc. Method of treating pain or interstitial cystitis using indole compound
JP7322007B2 (ja) * 2018-05-25 2023-08-07 日本たばこ産業株式会社 インドール化合物を含むネフローゼ症候群の治療又は予防剤
WO2019225740A1 (ja) 2018-05-25 2019-11-28 日本たばこ産業株式会社 インドール化合物を含む多発性硬化症の治療又は予防剤
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
JP2023552863A (ja) * 2020-12-15 2023-12-19 ファイザー・インク ベンゾイミダゾール誘導体および皮膚疾患の処置のためのitkの阻害剤としてのそれらの使用
EP4263538A1 (en) * 2020-12-15 2023-10-25 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
CN117693502A (zh) * 2021-05-03 2024-03-12 纽力克斯治疗公司 用于抑制或降解itk的化合物、包含其的组合物、其制备方法及其使用方法
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
EP4419520A2 (en) * 2021-10-19 2024-08-28 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
EP4695241A1 (en) * 2023-04-13 2026-02-18 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254937A1 (en) * 2003-09-08 2007-11-01 Aventis Pharmaceuticals Inc. Thienopyrazoles
US20070293499A1 (en) * 2006-05-18 2007-12-20 Mannkind Corporation Intracellular Kinase Inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
NZ555911A (en) * 2002-01-07 2008-07-31 Eisai R&D Man Co Ltd Deazapurines and uses thereof
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2006237920A1 (en) * 2005-04-19 2006-10-26 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compound
WO2007076228A2 (en) 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
JPWO2008047831A1 (ja) * 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254937A1 (en) * 2003-09-08 2007-11-01 Aventis Pharmaceuticals Inc. Thienopyrazoles
US20070293499A1 (en) * 2006-05-18 2007-12-20 Mannkind Corporation Intracellular Kinase Inhibitors

Also Published As

Publication number Publication date
JP5734628B2 (ja) 2015-06-17
AU2010323579C1 (en) 2016-11-03
JP2018158935A (ja) 2018-10-11
RS54910B1 (sr) 2016-10-31
PH12012501021A1 (en) 2013-01-14
JP2020079276A (ja) 2020-05-28
PL2505586T3 (pl) 2016-12-30
DK2505586T3 (en) 2016-05-30
HRP20160579T1 (hr) 2016-07-29
RU2556216C2 (ru) 2015-07-10
EP2505586A4 (en) 2013-05-15
AU2010323579A1 (en) 2012-07-19
IL220009A (en) 2017-08-31
PT2505586E (pt) 2016-06-03
EP3766877A1 (en) 2021-01-20
MY161095A (en) 2017-04-14
BR112012012529B1 (pt) 2021-10-26
JP2021091718A (ja) 2021-06-17
RU2012126129A (ru) 2013-12-27
JP2015172051A (ja) 2015-10-01
AU2010323579B2 (en) 2016-05-19
WO2011065402A1 (ja) 2011-06-03
AR079164A1 (es) 2011-12-28
SMT201600258B (it) 2016-08-31
US20130116240A1 (en) 2013-05-09
ME02447B (me) 2016-09-20
IL220009A0 (en) 2012-07-31
US20200255408A1 (en) 2020-08-13
CY1117559T1 (el) 2017-04-26
BR112012012529A2 (pt) 2016-05-03
NZ600840A (en) 2014-01-31
US20180362506A1 (en) 2018-12-20
PE20121358A1 (es) 2012-10-23
HUE028016T2 (en) 2016-11-28
US20210284627A1 (en) 2021-09-16
EP2505586B1 (en) 2016-03-02
EP3059234A1 (en) 2016-08-24
US8299070B2 (en) 2012-10-30
EP2505586A1 (en) 2012-10-03
JP2011132222A (ja) 2011-07-07
CN102712624A (zh) 2012-10-03
KR20120096540A (ko) 2012-08-30
MX2012006017A (es) 2012-06-25
KR101766502B1 (ko) 2017-08-08
CN102712624B (zh) 2014-06-04
JP2017039761A (ja) 2017-02-23
CO6541645A2 (es) 2012-10-16
CA2781660A1 (en) 2011-06-03
CL2012001328A1 (es) 2012-10-05
HK1174025A1 (en) 2013-05-31
CA2781660C (en) 2018-06-26
ES2572935T3 (es) 2016-06-03
US20170267662A1 (en) 2017-09-21
TW201124378A (en) 2011-07-16
US20110306599A1 (en) 2011-12-15
SI2505586T1 (sl) 2016-08-31

Similar Documents

Publication Publication Date Title
TWI491591B (zh) 吲哚化合物及其醫藥用途
TWI485150B (zh) 三唑并吡啶化合物及其作為脯胺醯基羥化酶抑制劑或紅血球生成素生產誘導劑之作用
CN101723936B (zh) 激酶抑制剂及其在药学中的用途
CA2399136A1 (en) 1h-imidazopyridine derivatives
JP6250667B2 (ja) 新しい抗菌化合物
BR112014003146B1 (pt) 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos composto e processos para preparação destes
KR20050121681A (ko) 면역조절 헤테로고리 화합물
WO2007007778A1 (ja) プロスタグランジンd合成酵素を阻害するベンゾイミダゾール化合物
JP6250668B2 (ja) 新しい抗菌化合物
HK1174025B (en) Indole compound and pharmaceutical use thereof
JPH08500129A (ja) チエニルチアゾール誘導体